Sharekhan has given Buy recommendation for Cipla with a target price of Rs. 1225 in its research report issued on Sep 09, 2022

Sharekhan’s research report on Cipla

Cipla’s Annual report for Fy22 has mentioned of significant progress across all strategic areas whilst navigating tough external environment. Going ahead the commentary around growth prospects stays bright and future growth of the company would be guided by Cipla’s 10 strategic business objective around passion, economic engine and capabilities. The outlook for US business is strong backed by growth in the respiratory products and highvalue launches being lined up in H2FY23 in the US markets, while it expects to outperform growth in the domestic markets.


We maintain Buy on Cipla with a revised PT of Rs 1225.

Leave a Reply

Your email address will not be published. Required fields are marked *